MX2009012092A - Vm23 y vm24, dos peptidos del veneno de alacran que bloquean con alta selectividad a los canales de potasio (subtipo kv1.3) de los linfocitos t humanos y disminuyen la reaccion in vivo de dth en ratas. - Google Patents
Vm23 y vm24, dos peptidos del veneno de alacran que bloquean con alta selectividad a los canales de potasio (subtipo kv1.3) de los linfocitos t humanos y disminuyen la reaccion in vivo de dth en ratas.Info
- Publication number
- MX2009012092A MX2009012092A MX2009012092A MX2009012092A MX2009012092A MX 2009012092 A MX2009012092 A MX 2009012092A MX 2009012092 A MX2009012092 A MX 2009012092A MX 2009012092 A MX2009012092 A MX 2009012092A MX 2009012092 A MX2009012092 A MX 2009012092A
- Authority
- MX
- Mexico
- Prior art keywords
- potassium channels
- peptides
- kvi
- rats
- responses
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
- C07K14/43513—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae
- C07K14/43522—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae from scorpions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
- G01N33/505—Cells of the immune system involving T-cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
- G01N33/9493—Immunosupressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/24—Immunology or allergic disorders
- G01N2800/245—Transplantation related diseases, e.g. graft versus host disease
Abstract
Los canales de potasio Kv1.3 se sabe que están implicados en enfermedades inmunológicas y el rechazo del injerto. Aquí se divulgan péptidos capaces de bloquear con gran afinidad y especificidad a los canales de potasio Kv1.3, sus composiciones farmacéuticas, y métodos para su uso para bloquear canales de potasio Kv1.3, para tratar varias condiciones inmunológicas y para aplicaciones de diagnóstico. También son revelados los métodos para su síntesis química y correcto plegamiento. Los péptidos ejemplares corresponden a los componentes proteicos (Vm23 y Vm24) aislados del veneno del alacrán mexicano Vaejovis mexicanus smithi. Vm23 y Vm24 se unen a los canales hKv1.3 de forma casi irreversible, mostrando un valor de Kd en el orden del rango de 3 pico molar, cuando se aplica a los linfocitos humanos en cultivo in vitro. Vm24 fue químicamente sintetizado y utilizado en experimentos in vivo para tratar con éxito a ratas sensibilizadas (en la respuesta a DTH). Ni Vm24 ni Vm24 sintética es tóxico para los ratones cuando se inyecta en concentraciones relativamente altas (ensayadas hasta 10.000 microgramos por kilogramo de peso corporal del ratón). Estos péptidos (Vm24 y Vm23) y sus análogos funcionales equivalentes con al menos un 83% de identidad de secuencias pares son compuestos lideres, candidatos para el tratamiento de diversas condiciones inmunológicas y aplicaciones de diagnóstico.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/IB2007/001544 WO2008139243A1 (en) | 2007-05-14 | 2007-05-14 | Vm23 and vm24, two scorpion peptides that block human t-lymphocyte potassium channels (sub-type kv1.3) with high selectivity and decrease the in vivo dth-responses in rats |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2009012092A true MX2009012092A (es) | 2010-02-12 |
Family
ID=38882810
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2009012092A MX2009012092A (es) | 2007-05-14 | 2007-05-14 | Vm23 y vm24, dos peptidos del veneno de alacran que bloquean con alta selectividad a los canales de potasio (subtipo kv1.3) de los linfocitos t humanos y disminuyen la reaccion in vivo de dth en ratas. |
Country Status (17)
Country | Link |
---|---|
US (1) | US8394770B2 (es) |
EP (1) | EP2158213B1 (es) |
JP (1) | JP5249319B2 (es) |
KR (1) | KR101524517B1 (es) |
CN (1) | CN101796069B (es) |
AT (1) | ATE537185T1 (es) |
AU (1) | AU2007353147B2 (es) |
BR (1) | BRPI0721664A8 (es) |
CA (1) | CA2686216C (es) |
DK (1) | DK2158213T3 (es) |
EA (1) | EA020131B1 (es) |
ES (1) | ES2379500T3 (es) |
IL (1) | IL202113A (es) |
MX (1) | MX2009012092A (es) |
PT (1) | PT2158213E (es) |
WO (1) | WO2008139243A1 (es) |
ZA (1) | ZA200907909B (es) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1931806B1 (en) | 2005-10-07 | 2011-10-05 | California Institute Of Technology | Pkr activation via hybridization chain reaction |
WO2008144562A1 (en) | 2007-05-16 | 2008-11-27 | California Institute Of Technology | A versatile nucleic acid hairpin motif for programming biomolecular self-assembly pathways |
EP2229473A4 (en) | 2007-12-07 | 2011-02-02 | Steven A Goldstein | IDENTIFICATION OF TOXIN LIGANDS |
US8962241B2 (en) * | 2010-07-20 | 2015-02-24 | California Institute Of Technology | Triggered molecular geometry based bioimaging probes |
US9834439B2 (en) | 2010-07-20 | 2017-12-05 | California Institute Of Technology | Biomolecular self-assembly |
US8924325B1 (en) * | 2011-02-08 | 2014-12-30 | Lockheed Martin Corporation | Computerized target hostility determination and countermeasure |
US9856472B2 (en) | 2013-07-01 | 2018-01-02 | California Institute Of Technology | Small conditional RNAs |
GB201408135D0 (en) * | 2014-05-08 | 2014-06-25 | Conogenetix Biosciences Gmbh | Kv1.3 potassium channel antagonists |
US10246496B2 (en) * | 2014-08-15 | 2019-04-02 | La Trobe University | Potassium channel blockers and use thereof in the treatment of autoimmune diseases |
WO2018009463A2 (en) | 2016-07-05 | 2018-01-11 | California Institute Of Technology | Fractional initiator hybridization chain reaction |
US10815519B2 (en) | 2016-08-30 | 2020-10-27 | California Institute Of Technology | Immunohistochemistry via hybridization chain reaction |
CN110357950B (zh) * | 2019-07-29 | 2023-04-25 | 武汉大学 | 酸性氨基酸扫描法设计的免疫抑制多肽及应用 |
US11873485B2 (en) | 2021-01-26 | 2024-01-16 | California Institute Of Technology | Allosteric conditional guide RNAs for cell-selective regulation of CRISPR/Cas |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5494895A (en) * | 1993-07-22 | 1996-02-27 | Merck & Co., Inc. | Scorpion peptide margatoxin with immunosuppressant activity |
WO1998029446A1 (fr) * | 1996-12-26 | 1998-07-09 | Suntory Limited | Neuropeptides provenant du scorpion |
US7833979B2 (en) * | 2005-04-22 | 2010-11-16 | Amgen Inc. | Toxin peptide therapeutic agents |
-
2007
- 2007-05-14 WO PCT/IB2007/001544 patent/WO2008139243A1/en active Application Filing
- 2007-05-14 ES ES07734817T patent/ES2379500T3/es active Active
- 2007-05-14 EP EP07734817A patent/EP2158213B1/en active Active
- 2007-05-14 MX MX2009012092A patent/MX2009012092A/es active IP Right Grant
- 2007-05-14 KR KR1020097026000A patent/KR101524517B1/ko active IP Right Grant
- 2007-05-14 US US12/599,978 patent/US8394770B2/en active Active
- 2007-05-14 PT PT07734817T patent/PT2158213E/pt unknown
- 2007-05-14 BR BRPI0721664A patent/BRPI0721664A8/pt not_active Application Discontinuation
- 2007-05-14 JP JP2010507993A patent/JP5249319B2/ja active Active
- 2007-05-14 CA CA2686216A patent/CA2686216C/en active Active
- 2007-05-14 AT AT07734817T patent/ATE537185T1/de active
- 2007-05-14 AU AU2007353147A patent/AU2007353147B2/en active Active
- 2007-05-14 CN CN200780053305.7A patent/CN101796069B/zh active Active
- 2007-05-14 EA EA200901530A patent/EA020131B1/ru unknown
- 2007-05-14 DK DK07734817.5T patent/DK2158213T3/da active
-
2009
- 2009-11-11 ZA ZA200907909A patent/ZA200907909B/xx unknown
- 2009-11-12 IL IL202113A patent/IL202113A/en not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
EP2158213B1 (en) | 2011-12-14 |
IL202113A (en) | 2013-01-31 |
JP5249319B2 (ja) | 2013-07-31 |
EP2158213A1 (en) | 2010-03-03 |
EA020131B1 (ru) | 2014-08-29 |
EA200901530A1 (ru) | 2011-08-30 |
PT2158213E (pt) | 2012-03-27 |
KR101524517B1 (ko) | 2015-06-10 |
CN101796069A (zh) | 2010-08-04 |
BRPI0721664A8 (pt) | 2019-01-22 |
DK2158213T3 (da) | 2012-04-10 |
ATE537185T1 (de) | 2011-12-15 |
US8394770B2 (en) | 2013-03-12 |
BRPI0721664A2 (pt) | 2013-01-22 |
WO2008139243A1 (en) | 2008-11-20 |
US20110059064A1 (en) | 2011-03-10 |
JP2010528988A (ja) | 2010-08-26 |
IL202113A0 (en) | 2010-06-16 |
AU2007353147B2 (en) | 2014-04-03 |
CN101796069B (zh) | 2014-02-19 |
CA2686216A1 (en) | 2008-11-20 |
ES2379500T3 (es) | 2012-04-26 |
AU2007353147A1 (en) | 2008-11-20 |
ZA200907909B (en) | 2010-07-28 |
KR20100023867A (ko) | 2010-03-04 |
CA2686216C (en) | 2016-04-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2009012092A (es) | Vm23 y vm24, dos peptidos del veneno de alacran que bloquean con alta selectividad a los canales de potasio (subtipo kv1.3) de los linfocitos t humanos y disminuyen la reaccion in vivo de dth en ratas. | |
Smyth et al. | Reactions of N-ethylmaleimide with peptides and amino acids | |
Konno et al. | Crotalphine, a novel potent analgesic peptide from the venom of the South American rattlesnake Crotalus durissus terrificus | |
Loughnan et al. | Identification of a novel class of nicotinic receptor antagonists: dimeric conotoxins VxXIIA, VxXIIB, and VxXIIC from Conus vexillum | |
BRPI0413276A (pt) | derivado de insulina, complexo de zinco do mesmo, composição farmacêutica, e, método para tratar diabete em um paciente | |
PE20100684A1 (es) | Anticuerpo anti b-4-amiloide que contiene asparagina glicosilada en la region variable de vh | |
WO2004066932A3 (en) | Composition for and treatment of demyelinating diseases and paralysis by administration of remyelinating agents | |
JP2013504318A5 (es) | ||
EP1572937A4 (en) | HYBRID POLYPEPTIDES TRANSPLANTED WITH MOTIVES AND USES THEREOF | |
WO2007054257A3 (en) | Indene derivatives, their preparation and use as medicaments | |
Kopeyan et al. | Characterization of toxin III of the scorpion Leiurus quinquestriatus quinquestriatus: a new type of alpha‐toxin highly toxic both to mammals and insects | |
ATE192037T1 (de) | Verwendung von arginin als immunstimulator | |
RU2016130108A (ru) | Конъюгаты полипептидного токсина и антитела, соединенных ковалентной связью | |
AU2021205415A8 (en) | Methods for treating inflammatory bowel diseases with α4β7 integrin antagonists | |
BRPI0409928A8 (pt) | compostos, enantiômeros, composição farmacêutica, uso de compostos, processo para a fabricação de compostos, e, modificação dos processos | |
AYEB et al. | Differential effects of defined chemical modifications on antigenic and pharmacological activities of scorpion α and β toxins | |
HUP9901411A2 (hu) | Aktív sündisznófehérje konjugátum, eljárás ennek előállítására és felhasználása | |
AR045765A1 (es) | Moleculas de union a cd45 y uso terapeutico | |
BR9913092A (pt) | Procedimento para a purificação cromotográficade insulinas | |
CN114106088A (zh) | 基于溴甲基吡嗪的药物偶联物及adc | |
BR0316599A (pt) | Agentes de alvejamento anti-linfoma com funções efetoras e de afinidade ligadas por um reagente trifuncional | |
Remenyi et al. | CIDP cured by allogeneic hematopoietic stem cell transplantation | |
BR0111726A (pt) | Derivados de biotina | |
EP3468563A1 (en) | Compounds for delivering glutathione to a target and methods of making and using the same | |
CU23816A3 (es) | Vm23 y vm24, dos péptidos del veneno de alacrán que bloquean con alta selectividad a los canales de potasio (subtipo kv1.3) de los linfocitos t humanos y disminuyen la reacción in vivo de dth en ratas |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |